[1]谢晓曦,李 奥,路 云.体外诊断试剂省级集中带量采购现状分析 ——基于卫生政策三角形框架[J].卫生经济研究,2025,42(06):35-39.
　XIE Xiaoxi,LI Ao,LU Yun.Analysis of Provincial-Level Centralized Volume-based Procurement of In Vitro Diagnostic Reagents ——Based on the Health Policy Triangle Framework[J].Journal Press of Health Economics Research,2025,42(06):35-39.
点击复制

体外诊断试剂省级集中带量采购现状分析
——基于卫生政策三角形框架

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年06期
页码:
35-39
栏目:
药械管理
出版日期:
2025-05-29

文章信息/Info

Title:
Analysis of Provincial-Level Centralized Volume-based Procurement of In Vitro Diagnostic Reagents
——Based on the Health Policy Triangle Framework
作者:
谢晓曦1; 李 奥1; 路 云1
1.中国药科大学国际医药商学院， 江苏 南京 211198
Author(s):
XIE Xiaoxi;  LI Ao;  LU Yun
International Pharmaceutical Business School, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
体外诊断试剂; 集中带量采购; 卫生政策三角形框架; 采购规则
Keywords:
in vitro diagnostic reagents;  centralized volume-based procurement;  health policy triangle framework;  procurement rules
分类号:
R19
文献标志码:
A
摘要:
目的：分析我国体外诊断试剂集采现状，为优化集采政策提供建议。方法：收集2021—2024年省级层面体外诊断试剂集采政策文件，基于卫生政策三角形框架，从政策环境、政策过程、政策内容和利益相关者四个方面进行分析。结果：体外诊断试剂集采处于起步阶段，政策环境方面存在指导性政策文件缺失，行业标准未统一的问题；政策过程方面存在配套措施不完善的问题；政策内容方面存在采购品种覆盖少、采购规则有待细化、政策公开不足的问题；利益相关者之间存在利益冲突。结论：加强治理，优化体外诊断试剂集采政策环境，健全配套措施，推动多种采购模式并行，协调利益相关者，合力推进集采政策落地实施。
Abstract:
Objective To analyze the current situation of provincial-level centralized volume-based procurement of in vitro diagnostic reagents in China, and to provide suggestions for optimizing the policy for centralized procurement. Methods The policy documents related to provincial-level centralized procurement of in vitro diagnostic reagents from 2021 to 2024 were collected. Based on the health policy triangle framework, the policies were analyzed in terms of policy environment, policy process, policy content and stakeholders. Results The centralized procurement of in vitro diagnostic reagents was in the initial stage. In terms of the policy environment, there were issues such as the lack of guiding policy documents and the absence of unified industry standards. Regarding the policy process, there were still gaps in the supporting measures. In terms of policy content, problems such as insufficient coverage of procurement varieties, the need for more refined procurement rules, and inadequate policy transparency remained. As for stakeholders, there were conflicts of interest among different groups. Conclusion It is necessary to strengthen governance, optimize the policy environment for centralized procurement of in vitro diagnostic reagent procurement, improve supporting measures, promote multiple procurement modes in parallel, coordinate stakeholders, and make joint efforts to promote the implementation of the policy for centralized procurement.

参考文献/References:

[1] 国家市场监督管理总局令（第48号）体外诊断试剂注册与备案管理办法[EB/OL].（2021-11-30）[2024-11-10].https://www.gov.cn/gongbao/content/2021/content_5654784.htm.
[2] 中国体外诊断行业年度报告（2023版）[R].全国卫生产业企业管理协会医学检验产业分会，2024.
[3] 虞丽娟，陈思思，王悦敏.公立医院体外诊断试剂全生命周期成本管理研究[J].卫生经济研究，2024，41（07）：75-79.
[4] Walt G,Gilson L.Reforming the health sector in developing countries:The central role of policy analysis[J].Health Policy and Planning,1994,4(09):353-370.
[5] 中共中央 国务院关于深化医疗保障制度改革的意见[EB/OL]. （2020-03-05）[2024-11-10].https://www.gov.cn/zhengce/2020-03/05/content_5487407.htm.
[6] China In-vitro Diagnostics Market Size & Share Analysis-Growth Trends & Forecasts(2024-2029)[R].Mordor Intelligence, 2024.
[7] 胡宏伟，王爽.关于我国体外诊断试剂集采的几点思考[J].中国医疗保险，2022（06）：48-53.
[8] 谢金平，张雪瑞，张赫，等.国家药品集中采购政策的主要利益相关者分析[J].中国药房，2021，32（21）：2677-2682.
[9] 谭清立，周芷婷.医用耗材带量采购的医保支付政策研究[J].卫生经济研究，2021，38（11）：6-9.
[10] 方中坚，王彩依，沈晨，等.高值医用耗材集采现状、问题及对策[J].卫生经济研究，2023，40（09）：23-25，28.

相似文献/References:

[1]郑洋洋,丁锦希,李佳明,等.高值耗材实施集中带量采购的主要障碍及对策研究[J].卫生经济研究,2021,38(4):35.
　ZHENG Yang-yang,DING Jin-xi,LI Jia-ming,et al.Research on the Main Obstacles and Countermeasures of Centralized Quantity Purchase of High Value Medical Consumables[J].Journal Press of Health Economics Research,2021,38(06):35.
[2]周菁菁,谈在祥.国家组织冠脉支架集中带量采购的实施情况及建议[J].卫生经济研究,2021,38(11):3.
　ZHOU Jing-jing,TAN Zai-xiang.Implementation and Suggestions of Centralized Volume-based Procurement of Coronary Stent by National Organization[J].Journal Press of Health Economics Research,2021,38(06):3.
[3]赵予涵,林燕铭,谭艳芬.高值医用耗材治理背景下老年性白内障手术费用研究[J].卫生经济研究,2022,39(1):40.
　ZHAO Yu-han,LIN Yan-ming,TAN Yan-fen.Study on the Cost of Senile Cataract Surgery Under the High-value Medical Consumables Governance[J].Journal Press of Health Economics Research,2022,39(06):40.
[4]冷楠楠,邱英鹏,赵羽西,等.冠脉支架集中带量采购对医疗服务供给的潜在影响分析[J].卫生经济研究,2022,39(5):1.
　LEN Nan-nan,QIU Ying-peng,ZHAO Yu-xi,et al.Analysis of the Potential Impact of the Policy of Centralized Procurement of Coronary Stents on the Provision of Medical Services[J].Journal Press of Health Economics Research,2022,39(06):1.
[5]蒋范黎,肖 月,赵羽西,等.集采背景下经皮冠脉支架植入术成本测算及建议[J].卫生经济研究,2022,39(5):4.
　JIANG Fan-li,XIAO Yue,ZHAO Yu-xi,et al.The Cost Calculation and Analysis of Percutaneous Coronary Intervention under the Background of Centralized Procurement of Stents[J].Journal Press of Health Economics Research,2022,39(06):4.
[6]罗婷婷,王秀英,吴伟旋,等.医院不计价及打包收费耗材的管理现状及对策[J].卫生经济研究,2022,39(5):91.
　LUO Ting-ting,WANG Xiu-ying,WU Wei-xuan,et al.Management Status and Improvement Suggestions of Non-priced and Packaged Charging Consumables[J].Journal Press of Health Economics Research,2022,39(06):91.
[7]黄晓青,王煜昊,王丽娜,等.医用耗材集采背景下按病种分值付费优化方案研究 ——以冠状动脉支架为例[J].卫生经济研究,2022,39(10):16.
　HUANG Xiaoqing,WANG Yuhao,WANG Lina,et al.Research on Policy Optimization of Diagnosis-Intervention Packet Based the Volume-Based Procurement of Medical Comsumables ——Taking Coronary Stents as an Example[J].Journal Press of Health Economics Research,2022,39(06):16.
[8]孙李丽,毛 英,张馨怡,等.国家集中带量采购冠脉支架对住院费用的影响研究[J].卫生经济研究,2023,40(5):55.
　SUN Lili,MAO Ying,ZHANG Xinyi,et al.Study on the Effect of National Centralized Volume-based Procurement of Coronary Stents on Hospitalization Costs[J].Journal Press of Health Economics Research,2023,40(06):55.
[9]李 洁,周胜男,孙源源.基于政策工具理论的中成药集中带量采购政策设计研究[J].卫生经济研究,2023,40(6):13.
　LI Jie,ZHOU Shengnan,SUN Yuanyuan.Study on the Policy Design of Centralized Volume-based Procurement of Chinese Patent Medicine Based on the Policy Tools Theory[J].Journal Press of Health Economics Research,2023,40(06):13.
[10]徐露露,张 钿,陈井婵,等.医保战略性购买对医药企业创新的影响研究[J].卫生经济研究,2023,40(12):7.
　XU Lulu,ZHANG Tian,CHEN Jingchan,et al.Study on the Impact of Strategic Purchase of Medical Insurance on Innovation of Pharmaceutical Enterprises[J].Journal Press of Health Economics Research,2023,40(06):7.

更新日期/Last Update: 2025-05-29